Related Experiment Video

Updated: Jun 19, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues

Mini Thomas1, Sumith A Kularatne, Longwu Qi

  • 1Department of Chemistry, Purdue University, West Lafayette, Indiana, USA.

Annals of the New York Academy of Sciences
|October 3, 2009
PubMed

Insights

Researchers developed a novel method to deliver small interfering RNA (siRNA) directly to cancer cells. By attaching cancer-targeting ligands like folic acid to siRNA, they achieved efficient and specific delivery for potential cancer therapies.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Oncology

Background:

  • Clinical applications of small interfering RNA (siRNA) are significantly limited by challenges in targeted delivery to cancer cells.
  • Existing strategies for delivering chemotherapeutic agents involve tumor-specific ligands, with some already in clinical trials.

Purpose of the Study:

  • To develop an efficient method for targeting siRNA to malignant cells and tissues.
  • To overcome the primary delivery obstacles hindering the clinical use of siRNA therapeutics.

Main Methods:

  • Covalent conjugation of small-molecular-weight, high-affinity ligands, specifically folic acid and DUPA (2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid), to siRNA molecules.
  • Utilizing folic acid to target folate receptors overexpressed on various cancer types.
  • Employing DUPA to target prostate-specific membrane antigen (PSMA) found on prostate cancers and tumor neovasculature.

Main Results:

  • Demonstrated successful receptor-mediated targeting of siRNA to cancer tissues both in vitro and in vivo.
  • Showcased the efficacy of ligand-conjugated siRNA in achieving specific delivery to cancer cells.
  • Validated the potential of folic acid and DUPA as effective targeting moieties for siRNA delivery.

Conclusions:

  • Ligand-mediated covalent conjugation offers a promising strategy for overcoming siRNA delivery challenges in cancer therapy.
  • This approach enables precise targeting of siRNA to specific cancer types and tumor neovasculature.
  • The developed method holds significant potential for advancing the clinical application of siRNA-based cancer treatments.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...